Loading clinical trials...
Loading clinical trials...
A Phase II, Two-Part, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS) Undergoing Endovascular Thrombectomy (EVT)
Conditions
Interventions
LT3001 Drug Product
Placebo
Locations
2
United States
CHI Memorial Hospital
Chattanooga, Tennessee, United States
Taichung Medical University
Taichung, Taiwan
Start Date
August 11, 2022
Primary Completion Date
March 31, 2026
Completion Date
March 31, 2026
Last Updated
June 5, 2025
NCT07253181
NCT06990867
NCT07001267
NCT03153683
NCT07371624
NCT05847699
Lead Sponsor
Lumosa Therapeutics Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions